INS and type 2 diabetes mellitus: Furthermore, metformin has several advantages in treating T2DM and associated cancer risks as compared to exogenous insulin and insulin secretalogues such as sulfonylurea drugs, which are reported to increase cancer risk and recurrence [23, 24].